Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (371-380 of 446) with videos related to

Pageof 45
Sort By:
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
JCO Oncology Practice|April 15, 2025
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|April 5, 2019
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapyMarcella A Tschautscher, Dragan Jevremovic, Vincent Rajkumar, et al.
American Journal of Hematology|October 26, 2021
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosisEli Muchtar, Amber B Koehler, Michael J Johnson, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 26, 2019
Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Pageof 45

Showing results (371-380 of 446) with videos related to

Sort By:
Pageof 45
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
JCO Oncology Practice|April 15, 2025
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|April 5, 2019
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapyMarcella A Tschautscher, Dragan Jevremovic, Vincent Rajkumar, et al.
American Journal of Hematology|October 26, 2021
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosisEli Muchtar, Amber B Koehler, Michael J Johnson, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 26, 2019
Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Pageof 45